AMAP 102

Drug Profile

AMAP 102

Alternative Names: AMAP102

Latest Information Update: 31 Jul 2015

Price : $50

At a glance

  • Originator AnaMar AB
  • Class Anti-inflammatories; Antirheumatics; Small molecules
  • Mechanism of Action Serotonin 2B receptor antagonists; Serotonin 2C receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes
  • Available For Licensing Yes

Highest Development Phases

  • Phase II Musculoskeletal pain
  • Phase I Rheumatoid arthritis

Most Recent Events

  • 31 Jul 2015 Phase-II development is ongoing for Musculoskeletal pain (associated with osteoarthritis) in Europe
  • 30 Oct 2014 Top-line efficacy and adverse events data from a phase II trial in Musculoskeletal pain (pain associated with osteoarthritis) released by AnaMar
  • 01 Jul 2014 AnaMar completes a phase II trial in Musculoskeletal pain in Poland, Germany and Sweden (EudraCT2012-001769-34)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top